Rep. Lloyd Doggett Acquires Shares of Johnson & Johnson (NYSE:JNJ)

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on July 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on June 9th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 6/18/2026.
• Purchased $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 6/12/2026.
• Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 6/10/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 5/15/2026.

Johnson & Johnson Trading Up 3.1%

NYSE JNJ opened at $267.35 on Wednesday. Johnson & Johnson has a 52 week low of $154.21 and a 52 week high of $269.43. The company has a 50 day moving average price of $235.09 and a 200 day moving average price of $232.13. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The firm has a market cap of $643.56 billion, a PE ratio of 30.91, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period in the previous year, the company earned $2.77 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts and market commentary highlight stronger outlooks, higher price targets, and solid sales momentum, supporting investor confidence ahead of earnings.
• Positive Sentiment: J&J’s raised 2026 guidance and solid first-quarter revenue growth have reinforced the view that the company can sustain earnings and sales growth.
• Positive Sentiment: Investors continue to favor defensive healthcare names with dependable cash flow and dividend appeal, which can add support to JNJ shares.
• Neutral Sentiment: Articles discussing JNJ as a top healthcare stock and a strong dividend name are broadly supportive, but they are more thematic than company-specific. Top Healthcare Stocks To Consider – July 7th
• Neutral Sentiment: One analysis argues JNJ may be 34% below fair value after the IMAAVY update, but this is an estimate rather than a confirmed catalyst. Johnson & Johnson (JNJ) Could Be 34% Below Fair Value Following IMAAVY Update
• Neutral Sentiment: There is also unusual put-option activity, which suggests some traders are hedging or betting on a pullback after the recent runup. Unusual Put Option Activity in Johnson & Johnson After JNJ Stock’s Recent Runup

Insider Activity

In related news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a report on Wednesday, April 15th. The Goldman Sachs Group lifted their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Daiwa Securities Group upped their target price on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research report on Thursday, April 16th. Finally, Guggenheim lifted their price target on Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $257.13.

Institutional Trading of Johnson & Johnson

Several large investors have recently made changes to their positions in the business. Blueline Advisors LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $25,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson in the 4th quarter worth about $26,000. DecisionPoint Financial LLC boosted its position in Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares in the last quarter. Family CFO Inc acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $31,000. Finally, Bay Harbor Wealth Management LLC increased its position in shares of Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after buying an additional 49 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas’ 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas’ 37th Congressional District. He declared candidacy for the 2026 election.

Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett’s career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.